AbbVie (ABBV) Stock

$193.04 1.29 (0.67%)
Market Cap: $341.13B | NYSE

AbbVie Chart


Company Profile

Price: $193.04

Market Cap: $341.13B

Exchange: NYSE

CEO: Mr. Robert A. Michael CPA

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 50.00K

Headquarters: North Chicago, IL

Website: AbbVie

Business Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie News

The Zacks Analyst Blog Walmart, Visa, AbbVie and AstroNova

Walmart, Visa, AbbVie and AstroNova are included in this Analyst Blog.

News image

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

News image

3 Top AI-Powered Biotech Stocks to Buy in February

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.

News image

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign

Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY.

News image

AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

News image

Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.

Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.

News image

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

News image

Buy, Sell, Or Hold ABBV Stock At $185?

AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectively.

News image

2 Undervalued Dividend Stocks Ready For A Major Comeback

The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong recovery potential. The other is a high-yield healthcare gem with anti-cyclical resilience. Both stocks offer market-beating potential, solid dividends, and long-term growth. They're perfect for balancing risk and reward in today's uncertain economy.

News image

Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.

Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start.

News image

AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance for 2025 and beyond is bullish, projecting high single-digit revenue growth through 2029, with Skyrizi and Rinvoq expected to generate $31 billion in combined sales by 2027. AbbVie's M&A strategy faced setbacks, notably with the Cerevel acquisition, but the company remains optimistic about future approvals and growth in oncology and neuroscience.

News image

AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds

AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion in revenue and $12.12-$12.32 adjusted EPS, and includes a worse outlook for Humira and additional headwinds from the Medicare Part D benefit redesign. Management expects high single-digit revenue growth through 2029, and over the next eight years, as there are no major products losing exclusivity throughout this period.

News image

AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.

News image

Why AbbVie Stock Is Jumping Today

Shares of AbbVie (ABBV 6.98%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day.

News image

AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript

AbbVie Inc. (NYSE:ABBV ) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Rob Michael - Chief Executive Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Carrie Strom - Senior Vice President of AbbVie, and President of Global Allergan Aesthetics Conference Call Participants Vamil Divan - Guggenheim Securities Chris Schott - J.P. Morgan Geoff Meacham - Citigroup Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Tim Anderson - Bank of America Chris Raymond - Piper Sandler Trung Huynh - UBS Chris Shibutani - Goldman Sachs Operator Good morning and thank you for standing by.

News image

PCE Inflation Increased In Line With Expectation

Today's pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The small-cap Russell 2000 is +5.

News image

December PCE Steady with Expectations; Plenty of Mixed Q4 Earnings

PCE results were as in-line with expectations as one could expect: +0.3% on headline month over month, +2.6% year over year.

News image

AbbVie shares rise as new drug sales offset Humira decline in Q4

Abbvie Inc (NYSE:ABBV) shares surged after the company posted a positive financial report for the fourth quarter, with sales growth of newer drugs offsetting a steep decline in Humira revenue.  Earnings per share of $2.16 topped estimates of $2.13, but marked a decline from $2.79 in the year-ago quarter.

News image

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie NYSE: ABBV is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira's patent cliff are behind it, with Skyrizi, Rinvoq, and the diversified portfolio of products gaining traction.

News image

AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook

AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to treat inflammation.

News image

Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News image

AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates

AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago.

News image

AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%

AbbVie's earnings topped estimates as it offered an upbeat view of 2025.

News image

AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.

News image

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense   Delivers Full-Year Net Revenues of $56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis    Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Humira Net Revenues Were $8.993 Billion; Global Skyrizi Net Revenues Were $11.718 Billion; Global Rinvoq Net Revenues Were $5.971 Billion    Full-Year Global Net Revenues from the Oncology Portfolio Were $6.555 Billion, an Increase of 10.8 Percent on a Reported Basis, or 12.0 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $3.347 Billion; Global Venclexta Net Revenues Were $2.583 Billion   Full-Year Global Net Revenues from the Neuroscience Portfolio Were $8.999 Billion, an Increase of 16.6 Percent on a Reported Basis, or 16.9 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $3.283 Billion; Global Vraylar Net Revenues Were $3.267 Billion ; Combined Global Ubrelvy and Qulipta Net Revenues were $1.664 Billion   Full-Year Global Net Revenues from the Aesthetics Portfolio Were $5.176 Billion, a Decrease of 2.2 Percent on a Reported Basis, or 0.6 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $2.720 Billion; Global Juvederm Net Revenues Were $1.177 Billion   Reports Fourth-Quarter Diluted Loss Per Share of $0.02 on a GAAP Basis, Inclusive of the Recent Partial Intangible Asset Impairment Charge Related to Emraclidine; Adjusted Diluted EPS of $2.16; These Results Include an Unfavorable Impact of $0.88 Per Share Related to Fourth-Quarter 2024 Acquired IPR&D and Milestones Expense    Delivers Fourth-Quarter Net Revenues of $15.102 Billion, an Increase of 5.6 Percent on a Reported Basis and 6.1 Percent on an Operational Basis   Provides 2025 Adjusted Diluted EPS Guidance Range of $12.12 to $12.32; Excludes Any Unfavorable Impact Related to Acquired IPR&D and Milestones Expense   Reaffirms Expectations for High Single-Digit Compound Annual Revenue Growth Rate through 2029; Raises 2027 Combined Sales Outlook for Skyrizi and Rinvoq to More Than $31 Billion; Updates Outlook for Aesthetics to Deliver High Single-Digit Compound Annual Revenue Growth Rate from 2025 through 2029 NORTH CHICAGO, Ill., Jan. 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2024.

News image

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.

News image

AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.

News image

I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from a fundamental truth: A sustainable high dividend yield often serves as a powerful indicator of intrinsic value.

News image

Why AbbVie Stock Popped While the Market Flopped on Monday

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (ABBV 3.88%) wasn't one of them. The storied pharmaceutical company saw its share price rise by almost 4%, on the back of a pair of pre-earnings price target bumps from analysts.

News image

AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive

AbbVie Inc. ABBV will release its full-year and fourth-quarter 2024 financial results on Friday, Jan. 31.

News image

AbbVie Earnings

This section highlights AbbVie's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 25, 2025
Time: Before Market
Est. EPS: $2.54
Status: Unconfirmed

Last Earnings Results

Date: January 31, 2025
EPS: $2.16
Est. EPS: $2.98
Revenue: $15.10B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-01-31 $2.98 $2.16
Read Transcript Q3 2024 2024-10-30 $2.92 $3.00
Read Transcript Q2 2024 2024-07-25 $2.57 $2.65
Read Transcript Q1 2024 2024-04-26 $2.26 $2.31
Read Transcript Q4 2023 2024-02-02 $2.76 $2.79
Read Transcript Q3 2023 2023-10-27 $2.86 $2.95
Read Transcript Q2 2023 2023-07-27 $2.79 $2.91
Read Transcript Q1 2023 2023-04-27 $2.44 $2.46

Financial Statements

Access annual & quarterly financial statements for AbbVie, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $54.32B $58.05B $56.20B $45.80B $33.27B
Cost of Revenue $20.41B $17.41B $17.45B $15.39B $7.44B
Gross Profit $33.90B $40.64B $38.75B $30.42B $25.83B
Gross Profit Ratio 62.42% 70.00% 68.96% 66.41% 77.64%
Research and Development Expenses $8.45B $6.51B $7.08B $6.56B $6.41B
General and Administrative Expenses $10.70B $13.26B $10.25B $9.50B $5.84B
Selling and Marketing Expenses $2.20B $2.00B $2.10B $1.80B $1.10B
Selling General and Administrative Expenses $12.87B $15.26B $12.35B $11.30B $6.94B
Other Expenses $- $56.00M $432.00M $-5.61B $-890.00M
Operating Expenses $21.15B $21.83B $19.86B $17.86B $12.46B
Cost and Expenses $41.56B $39.94B $38.27B $34.44B $20.28B
Interest Income $540.00M $186.00M $39.00M $174.00M $275.00M
Interest Expense $2.22B $2.23B $2.42B $2.45B $1.78B
Depreciation and Amortization $8.70B $8.47B $8.52B $6.47B $2.02B
EBITDA $17.31B $31.42B $28.28B $21.15B $16.26B
EBITDA Ratio 31.86% 45.79% 47.06% 15.17% 41.47%
Operating Income $12.76B $18.12B $17.92B $11.36B $12.98B
Operating Income Ratio 23.49% 31.21% 31.89% 24.81% 39.03%
Total Other Income Expenses Net $-6.51B $-4.64B $-4.93B $-7.96B $-4.56B
Income Before Tax $6.25B $13.48B $12.99B $3.40B $8.43B
Income Before Tax Ratio 11.51% 23.21% 23.11% 7.42% 25.33%
Income Tax Expense $1.38B $1.63B $1.44B $1.22B $544.00M
Net Income $4.86B $11.84B $11.54B $4.62B $7.88B
Net Income Ratio 8.95% 20.39% 20.54% 10.08% 23.69%
EPS $2.73 $6.65 $6.48 $2.73 $5.30
EPS Diluted $2.72 $6.63 $6.45 $2.72 $5.28
Weighted Average Shares Outstanding 1.77B 1.77B 1.77B 1.67B 1.48B
Weighted Average Shares Outstanding Diluted 1.77B 1.78B 1.78B 1.67B 1.48B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $14.46B $14.46B $12.31B $14.30B $13.93B $13.87B $12.22B $15.12B $14.81B $14.58B $13.54B $14.89B $14.34B $13.96B $13.01B $13.86B $12.90B $10.43B $8.62B $8.70B
Cost of Revenue $4.21B $2.18B $4.08B $2.39B $6.49B $4.24B $3.99B $4.17B $5.02B $4.17B $4.05B $4.32B $4.39B $4.52B $4.21B $4.68B $5.05B $3.71B $1.94B $2.01B
Gross Profit $10.25B $12.29B $8.23B $11.91B $7.44B $9.62B $8.24B $10.95B $9.79B $10.41B $9.49B $10.57B $9.95B $9.44B $8.80B $9.17B $7.85B $6.71B $6.68B $6.70B
Gross Profit Ratio 70.87% 84.95% 66.84% 83.32% 53.44% 69.42% 67.39% 72.42% 66.10% 71.41% 70.07% 70.98% 69.39% 67.60% 67.62% 66.20% 60.86% 64.40% 77.47% 76.95%
Research and Development Expenses $2.13B $1.92B $1.94B $1.92B $1.72B $1.73B $2.29B $1.79B $1.61B $1.61B $1.50B $1.83B $1.67B $1.80B $1.78B $1.89B $1.71B $1.58B $1.38B $1.54B
General and Administrative Expenses $- $- $- $1.41B $- $- $- $1.42B $- $- $- $1.16B $- $- $- $1.43B $- $- $1.70B $1.95B
Selling and Marketing Expenses $- $- $- $2.20B $- $- $- $2.00B $- $- $- $2.10B $- $- $- $1.80B $- $- $- $1.10B
Selling General and Administrative Expenses $4.21B $3.34B $3.30B $3.61B $3.37B $3.27B $3.04B $3.42B $3.30B $5.41B $3.13B $3.26B $3.08B $3.16B $2.84B $3.23B $2.85B $3.53B $1.70B $1.95B
Other Expenses $82.00M $-1.95B $-586.00M $-1.89B $95.00M $-1.41B $-10.00M $-1.00M $229.00M $-1.53B $776.00M $-216.00M $-21.00M $-2.66B $395.00M $-4.62B $-115.00M $-802.00M $-72.00M $-416.00M
Operating Expenses $6.42B $7.21B $5.24B $7.42B $5.09B $4.83B $5.32B $5.21B $5.15B $6.85B $4.62B $5.09B $5.26B $4.90B $4.62B $5.12B $4.55B $5.11B $3.07B $2.60B
Cost and Expenses $10.63B $10.46B $9.51B $11.11B $11.65B $9.35B $9.46B $9.62B $10.21B $11.29B $8.82B $9.81B $10.04B $9.52B $8.91B $10.11B $9.65B $9.67B $5.02B $4.75B
Interest Income $- $220.00M $207.00M $186.00M $157.00M $98.00M $99.00M $90.00M $63.00M $24.00M $9.00M $9.00M $11.00M $9.00M $10.00M $11.00M $10.00M $18.00M $135.00M $104.00M
Interest Expense $591.00M $726.00M $660.00M $564.00M $555.00M $552.00M $553.00M $566.00M $560.00M $556.00M $548.00M $580.00M $596.00M $615.00M $632.00M $629.00M $630.00M $632.00M $563.00M $559.00M
Depreciation and Amortization $2.08B $2.13B $2.07B $2.08B $2.23B $2.26B $2.13B $2.16B $2.21B $2.05B $2.05B $1.98B $2.13B $2.20B $2.21B $2.06B $2.29B $1.55B $559.00M $509.00M
EBITDA $4.93B $7.13B $5.56B $6.62B $4.71B $7.20B $5.80B $8.26B $7.24B $7.79B $7.27B $8.77B $7.04B $6.93B $6.68B $8.37B $5.84B $3.75B $4.20B $3.79B
EBITDA Ratio 34.11% 35.15% 41.13% 29.25% 17.53% 48.85% 40.04% 50.65% 45.96% 13.93% 50.01% 47.38% 44.85% 47.58% 48.56% 41.98% 42.99% 22.13% 48.29% 51.30%
Operating Income $3.83B $4.00B $2.80B $3.19B $2.28B $4.51B $2.77B $5.50B $4.60B $3.29B $4.72B $5.07B $4.31B $4.44B $4.10B $3.75B $3.25B $752.00M $3.60B $3.96B
Operating Income Ratio 26.49% 27.64% 22.73% 22.34% 16.38% 32.55% 22.64% 36.39% 31.08% 22.59% 34.84% 34.09% 30.02% 31.81% 31.54% 27.08% 25.23% 7.21% 41.80% 45.45%
Total Other Income Expenses Net $-1.75B $-1.85B $-1.04B $-1.98B $-328.00M $-1.90B $-2.29B $-2.54B $-203.00M $-2.11B $212.00M $-803.00M $-618.00M $-3.28B $-236.00M $-5.26B $-755.00M $-1.45B $-505.00M $-882.00M
Income Before Tax $2.08B $2.15B $1.75B $1.21B $1.95B $2.61B $475.00M $2.96B $4.40B $1.18B $4.93B $4.27B $3.69B $1.16B $3.87B $-1.51B $2.50B $-693.00M $3.10B $3.07B
Income Before Tax Ratio 14.41% 14.84% 14.26% 8.47% 14.02% 18.82% 3.89% 19.61% 29.71% 8.11% 36.41% 28.69% 25.71% 8.33% 29.72% -10.87% 19.38% -6.65% 35.94% 35.32%
Income Tax Expense $520.00M $773.00M $383.00M $388.00M $172.00M $583.00M $234.00M $493.00M $448.00M $255.00M $436.00M $226.00M $508.00M $394.00M $312.00M $1.54B $187.00M $46.00M $88.00M $273.00M
Net Income $1.56B $1.37B $1.37B $822.00M $1.78B $2.02B $239.00M $2.47B $3.95B $924.00M $4.49B $4.04B $3.18B $766.00M $3.55B $36.00M $2.31B $-738.00M $3.01B $2.80B
Net Income Ratio 10.80% 9.47% 11.12% 5.75% 12.77% 14.60% 1.96% 16.35% 26.66% 6.34% 33.17% 27.17% 22.17% 5.49% 27.31% 0.26% 17.89% -7.08% 34.92% 32.18%
EPS $0.88 $0.78 $0.77 $0.46 $1.00 $1.14 $0.13 $1.40 $2.23 $0.52 $2.54 $2.29 $1.78 $0.42 $2.00 $0.02 $1.30 $-0.45 $2.02 $1.89
EPS Diluted $0.88 $0.78 $0.77 $0.46 $1.00 $1.14 $0.13 $1.39 $2.22 $0.51 $2.53 $2.26 $1.78 $0.42 $1.99 $0.01 $1.29 $-0.45 $2.02 $1.88
Weighted Average Shares Outstanding 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.64B 1.48B 1.48B
Weighted Average Shares Outstanding Diluted 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.78B 1.78B 1.78B 1.78B 1.78B 1.78B 1.78B 1.78B 1.77B 1.78B 1.77B 1.65B 1.48B 1.49B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $12.81B $9.20B $9.75B $8.45B $39.92B
Short Term Investments $2.00M $28.00M $84.00M $30.00M $-
Cash and Short Term Investments $12.82B $9.23B $9.83B $8.48B $39.92B
Net Receivables $11.15B $11.25B $9.98B $8.82B $5.43B
Inventory $4.10B $3.58B $3.13B $3.31B $1.81B
Other Current Assets $4.93B $4.40B $4.99B $3.56B $2.35B
Total Current Assets $33.00B $28.46B $27.93B $24.17B $49.52B
Property Plant Equipment Net $4.99B $4.93B $5.11B $5.25B $2.96B
Goodwill $32.29B $32.16B $32.38B $33.12B $15.60B
Intangible Assets $55.61B $67.44B $75.95B $82.88B $18.65B
Goodwill and Intangible Assets $87.90B $99.59B $108.33B $116.00B $34.25B
Long Term Investments $304.00M $241.00M $277.00M $293.00M $93.00M
Tax Assets $- $- $- $- $-
Other Non-Current Assets $8.51B $5.57B $4.88B $4.85B $2.29B
Total Non-Current Assets $101.71B $110.34B $118.60B $126.39B $39.60B
Other Assets $- $- $- $- $-
Total Assets $134.71B $138.81B $146.53B $150.56B $89.11B
Account Payables $3.69B $2.93B $2.88B $2.28B $1.45B
Short Term Debt $7.19B $4.14B $12.49B $8.50B $3.75B
Tax Payables $- $- $- $- $-
Deferred Revenue $- $- $- $- $-
Other Current Liabilities $26.96B $22.47B $19.82B $17.88B $10.38B
Total Current Liabilities $37.84B $29.54B $35.19B $28.66B $15.59B
Long Term Debt $52.96B $59.91B $64.93B $78.41B $63.25B
Deferred Revenue Non-Current $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $2.19B $3.01B $3.65B $1.13B
Other Non-Current Liabilities $33.52B $32.07B $30.97B $30.40B $18.46B
Total Non-Current Liabilities $86.47B $91.98B $95.90B $108.81B $81.70B
Other Liabilities $- $- $- $- $-
Total Liabilities $124.31B $121.52B $131.09B $137.47B $97.29B
Preferred Stock $- $- $- $- $-
Common Stock $18.00M $18.00M $18.00M $18.00M $18.00M
Retained Earnings $-1.00B $4.78B $3.13B $1.05B $4.72B
Accumulated Other Comprehensive Income Loss $-2.31B $-2.20B $-2.90B $-3.12B $-3.60B
Other Total Stockholders Equity $13.65B $14.65B $15.16B $15.12B $-9.31B
Total Stockholders Equity $10.36B $17.25B $15.41B $13.08B $-8.17B
Total Equity $10.40B $17.29B $15.44B $13.10B $-8.17B
Total Liabilities and Stockholders Equity $134.71B $138.81B $146.53B $150.56B $89.11B
Minority Interest $37.00M $33.00M $28.00M $21.00M $-
Total Liabilities and Total Equity $134.71B $138.81B $146.53B $150.56B $89.11B
Total Investments $306.00M $269.00M $361.00M $323.00M $93.00M
Total Debt $59.38B $63.27B $76.68B $86.06B $66.73B
Net Debt $46.57B $54.07B $66.94B $77.61B $26.80B


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $7.26B $13.13B $18.07B $12.81B $13.29B $8.76B $6.71B $9.20B $11.83B $8.52B $6.10B $9.75B $12.18B $8.55B $9.76B $8.45B $7.89B $6.02B $41.14B $39.92B
Short Term Investments $28.00M $27.00M $2.00M $2.00M $3.00M $7.00M $11.00M $28.00M $47.00M $1.44B $1.47B $84.00M $67.00M $54.00M $22.00M $30.00M $60.00M $23.00M $- $-
Cash and Short Term Investments $7.29B $13.16B $18.07B $12.82B $13.29B $8.77B $6.72B $9.23B $11.88B $9.96B $7.57B $9.83B $12.25B $8.60B $9.78B $8.48B $7.95B $6.04B $41.14B $39.92B
Net Receivables $11.47B $11.72B $11.95B $11.15B $11.41B $11.49B $11.47B $11.25B $10.74B $11.24B $10.73B $9.98B $9.28B $9.91B $9.59B $8.82B $8.42B $8.35B $6.36B $5.43B
Inventory $4.45B $4.22B $4.25B $4.10B $3.98B $4.05B $3.83B $3.58B $3.17B $3.40B $3.48B $3.13B $3.09B $3.39B $3.27B $3.31B $3.47B $4.06B $1.84B $1.81B
Other Current Assets $4.58B $4.72B $4.61B $4.93B $4.54B $4.54B $4.46B $4.40B $4.57B $4.51B $4.72B $4.99B $4.33B $4.10B $3.93B $3.56B $3.17B $2.80B $2.41B $2.35B
Total Current Assets $27.79B $33.82B $38.87B $33.00B $33.22B $28.85B $26.49B $28.46B $30.36B $29.10B $26.51B $27.93B $28.96B $26.00B $26.57B $24.17B $23.01B $21.26B $51.76B $49.52B
Property Plant Equipment Net $5.14B $5.02B $4.98B $4.99B $4.93B $4.94B $4.93B $4.93B $4.89B $4.96B $5.08B $5.11B $5.13B $5.16B $5.19B $5.25B $4.99B $4.91B $2.96B $2.96B
Goodwill $35.30B $33.39B $33.43B $32.29B $32.09B $32.22B $32.22B $32.16B $31.73B $32.03B $32.30B $32.38B $32.30B $32.40B $32.35B $33.12B $42.80B $42.67B $15.56B $15.60B
Intangible Assets $66.65B $60.24B $62.23B $55.61B $58.60B $62.86B $64.85B $67.44B $68.72B $71.82B $73.99B $75.95B $77.46B $79.34B $81.29B $82.88B $74.64B $76.46B $18.20B $18.65B
Goodwill and Intangible Assets $101.94B $93.63B $95.65B $87.90B $90.69B $95.09B $97.07B $99.59B $100.45B $103.85B $106.28B $108.33B $109.75B $111.74B $113.64B $116.00B $117.44B $119.13B $33.76B $34.25B
Long Term Investments $267.00M $272.00M $305.00M $304.00M $275.00M $288.00M $257.00M $241.00M $235.00M $244.00M $260.00M $277.00M $272.00M $266.00M $305.00M $293.00M $246.00M $225.00M $78.00M $93.00M
Tax Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Assets $8.29B $9.20B $9.07B $8.51B $7.09B $6.20B $5.80B $5.57B $5.38B $5.03B $5.08B $4.88B $4.75B $4.81B $4.79B $4.85B $3.94B $4.01B $2.64B $2.29B
Total Non-Current Assets $115.64B $108.12B $110.00B $101.71B $103.00B $106.52B $108.06B $110.34B $110.96B $114.09B $116.70B $118.60B $119.90B $121.97B $123.93B $126.39B $126.61B $128.27B $39.44B $39.60B
Other Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $143.42B $141.94B $148.87B $134.71B $136.22B $135.37B $134.54B $138.81B $141.32B $143.19B $143.21B $146.53B $148.86B $147.97B $150.50B $150.56B $149.62B $149.53B $91.20B $89.11B
Account Payables $- $- $- $3.69B $- $- $- $2.93B $- $- $- $2.88B $- $- $- $2.28B $- $- $- $1.45B
Short Term Debt $12.57B $12.59B $10.20B $7.19B $5.12B $5.20B $2.80B $4.14B $9.21B $11.93B $9.95B $12.49B $6.67B $7.90B $11.35B $8.69B $4.78B $5.37B $3.76B $3.87B
Tax Payables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Revenue $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Current Liabilities $30.49B $29.33B $31.33B $26.96B $29.66B $27.04B $24.79B $22.47B $23.50B $22.54B $22.57B $19.82B $21.86B $20.78B $20.60B $17.70B $19.40B $19.27B $12.71B $10.26B
Total Current Liabilities $43.06B $41.91B $41.52B $37.84B $34.77B $32.24B $27.59B $29.54B $32.71B $34.47B $32.52B $35.19B $28.53B $28.68B $31.95B $28.66B $24.18B $24.65B $16.47B $15.59B
Long Term Debt $58.51B $58.05B $63.80B $52.96B $55.63B $55.81B $59.29B $59.91B $60.40B $61.00B $63.52B $64.93B $74.05B $74.24B $74.18B $78.41B $82.28B $82.06B $63.28B $63.25B
Deferred Revenue Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $2.75B $2.73B $2.72B $1.95B $2.04B $2.12B $2.11B $2.19B $1.97B $2.25B $2.83B $3.01B $3.60B $3.66B $3.77B $3.65B $4.49B $4.79B $959.00M $1.13B
Other Non-Current Liabilities $33.03B $32.43B $32.78B $33.52B $31.64B $32.29B $32.25B $32.07B $30.21B $30.77B $28.02B $30.97B $29.10B $28.80B $26.87B $30.40B $23.38B $23.31B $17.90B $18.46B
Total Non-Current Liabilities $94.29B $93.20B $99.31B $86.47B $89.32B $90.23B $93.65B $91.98B $92.59B $94.03B $94.38B $95.90B $106.75B $106.69B $104.82B $108.81B $110.15B $110.15B $82.14B $81.70B
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $137.35B $135.12B $140.83B $124.31B $124.09B $122.47B $121.24B $121.52B $125.30B $128.50B $126.90B $131.09B $135.28B $135.38B $136.77B $137.47B $134.33B $134.80B $98.61B $97.29B
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M $18.00M
Retained Earnings $-4.96B $-3.77B $-2.38B $-1.00B $933.00M $1.79B $2.39B $4.78B $4.95B $3.52B $5.10B $3.13B $1.60B $740.00M $2.29B $1.05B $3.33B $3.13B $5.97B $4.72B
Accumulated Other Comprehensive Income Loss $-2.33B $-2.51B $-2.45B $-2.31B $-2.35B $-2.25B $-2.23B $-2.20B $-3.44B $-3.20B $-2.98B $-2.90B $-3.16B $-3.10B $-3.29B $-3.12B $-3.26B $-3.44B $-3.70B $-3.60B
Other Total Stockholders Equity $13.31B $13.04B $12.83B $13.65B $13.50B $13.31B $13.10B $14.65B $14.47B $14.31B $14.15B $15.16B $15.09B $14.91B $14.70B $15.12B $15.18B $14.99B $-9.71B $-9.31B
Total Stockholders Equity $6.03B $6.78B $8.01B $10.36B $12.09B $12.87B $13.27B $17.25B $15.99B $14.65B $16.28B $15.41B $13.55B $12.57B $13.71B $13.08B $15.27B $14.71B $-7.42B $-8.17B
Total Equity $6.07B $6.82B $8.05B $10.40B $12.13B $12.90B $13.30B $17.29B $16.03B $14.69B $16.31B $15.44B $13.58B $12.59B $13.73B $13.10B $15.29B $14.73B $-7.42B $-8.17B
Total Liabilities and Stockholders Equity $143.42B $141.94B $148.87B $134.71B $136.22B $135.37B $134.54B $138.81B $141.32B $143.19B $143.21B $146.53B $148.86B $147.97B $150.50B $150.56B $149.62B $149.53B $91.20B $89.11B
Minority Interest $39.00M $43.00M $40.00M $37.00M $35.00M $32.00M $29.00M $33.00M $33.00M $35.00M $31.00M $28.00M $27.00M $25.00M $23.00M $21.00M $19.00M $24.00M $- $-
Total Liabilities and Total Equity $143.42B $141.94B $148.87B $134.71B $136.22B $135.37B $134.54B $138.81B $141.32B $143.19B $143.21B $146.53B $148.86B $147.97B $150.50B $150.56B $149.62B $149.53B $91.20B $89.11B
Total Investments $295.00M $299.00M $307.00M $306.00M $278.00M $295.00M $268.00M $269.00M $282.00M $1.68B $1.73B $361.00M $339.00M $320.00M $327.00M $323.00M $306.00M $248.00M $78.00M $93.00M
Total Debt $71.08B $70.63B $74.00B $59.38B $60.75B $61.02B $62.09B $63.27B $69.61B $72.93B $73.47B $76.68B $80.72B $82.14B $85.53B $86.06B $87.06B $87.43B $67.05B $66.73B
Net Debt $63.82B $57.50B $55.93B $46.57B $47.46B $52.26B $55.38B $54.07B $57.77B $64.41B $67.38B $66.94B $68.54B $73.59B $75.78B $77.61B $79.17B $81.42B $25.90B $26.80B

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $4.87B $11.85B $11.55B $4.62B $7.88B
Depreciation and Amortization $8.70B $8.47B $8.52B $6.47B $2.02B
Deferred Income Tax $-2.89B $-1.93B $-898.00M $-2.33B $700.00M
Stock Based Compensation $747.00M $671.00M $692.00M $753.00M $430.00M
Change in Working Capital $2.81B $-258.00M $-1.32B $106.00M $-1.33B
Accounts Receivables $66.00M $-1.46B $-1.32B $-929.00M $-74.00M
Inventory $-417.00M $-686.00M $-142.00M $-40.00M $-231.00M
Accounts Payables $3.84B $1.60B $1.63B $1.51B $-1.12B
Other Working Capital $-676.00M $278.00M $-1.49B $-439.00M $97.00M
Other Non Cash Items $8.60B $6.15B $4.24B $7.96B $3.62B
Net Cash Provided by Operating Activities $22.84B $24.94B $22.78B $17.59B $13.32B
Investments in Property Plant and Equipment $-777.00M $-695.00M $-787.00M $-798.00M $-552.00M
Acquisitions Net $-1.22B $-794.00M $-1.90B $-39.61B $-1.14B
Purchases of Investments $-77.00M $-1.44B $-119.00M $-61.00M $-583.00M
Sales Maturities of Investments $55.00M $1.53B $98.00M $1.52B $2.70B
Other Investing Activities $13.00M $774.00M $366.00M $1.39B $167.00M
Net Cash Used for Investing Activities $-2.01B $-623.00M $-2.34B $-37.56B $596.00M
Debt Repayment $-4.15B $-12.43B $-8.41B $-2.68B $26.25B
Common Stock Issued $- $- $- $- $-
Common Stock Repurchased $-1.97B $-1.49B $-934.00M $-978.00M $-629.00M
Dividends Paid $-10.54B $-10.04B $-9.26B $-7.72B $-6.37B
Other Financing Activities $-562.00M $-840.00M $-430.00M $-124.00M $-544.00M
Net Cash Used Provided by Financing Activities $-17.22B $-24.80B $-19.04B $-11.50B $18.71B
Effect of Forex Changes on Cash $5.00M $-62.00M $-97.00M $-5.00M $7.00M
Net Change in Cash $3.61B $-545.00M $1.30B $-31.48B $32.63B
Cash at End of Period $12.81B $9.20B $9.75B $8.45B $39.92B
Cash at Beginning of Period $9.20B $9.75B $8.45B $39.92B $7.29B
Operating Cash Flow $22.84B $24.94B $22.78B $17.59B $13.32B
Capital Expenditure $-777.00M $-695.00M $-787.00M $-798.00M $-552.00M
Free Cash Flow $22.06B $24.25B $21.99B $16.79B $12.77B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $1.56B $1.36B $1.36B $826.00M $1.78B $2.03B $241.00M $2.47B $3.95B $928.00M $4.49B $4.04B $3.18B $769.00M $3.56B $38.00M $2.31B $-739.00M $3.01B $2.80B
Depreciation and Amortization $2.08B $2.08B $2.07B $2.08B $2.23B $2.26B $2.13B $2.16B $2.21B $2.05B $2.05B $1.98B $2.13B $2.20B $2.21B $2.06B $2.29B $1.55B $559.00M $509.00M
Deferred Income Tax $-277.00M $-16.00M $-389.00M $-1.39B $-863.00M $-368.00M $-267.00M $-516.00M $-621.00M $-600.00M $-194.00M $-745.00M $-34.00M $-91.00M $-28.00M $-1.83B $-241.00M $-257.00M $- $-330.00M
Stock Based Compensation $181.00M $218.00M $348.00M $125.00M $130.00M $179.00M $313.00M $132.00M $126.00M $107.00M $306.00M $129.00M $135.00M $159.00M $269.00M $136.00M $162.00M $236.00M $219.00M $79.00M
Change in Working Capital $750.00M $-3.38B $247.00M $443.00M $2.64B $552.00M $-825.00M $843.00M $1.34B $-1.16B $-1.27B $-1.08B $1.71B $-990.00M $-956.00M $-922.00M $965.00M $149.00M $-86.00M $-322.00M
Accounts Receivables $344.00M $178.00M $-702.00M $339.00M $2.00M $-80.00M $-195.00M $-416.00M $357.00M $-611.00M $-785.00M $-749.00M $590.00M $-296.00M $-866.00M $-355.00M $-31.00M $482.00M $-1.02B $133.00M
Inventory $-64.00M $-52.00M $-75.00M $96.00M $-55.00M $-273.00M $-185.00M $-170.00M $-17.00M $-114.00M $-385.00M $-112.00M $219.00M $-62.00M $-187.00M $153.00M $111.00M $-197.00M $-107.00M $170.00M
Accounts Payables $267.00M $-1.70B $362.00M $179.00M $2.55B $1.57B $-465.00M $1.27B $778.00M $-190.00M $-258.00M $174.00M $1.15B $72.00M $236.00M $-389.00M $1.44B $-599.00M $1.06B $-539.00M
Other Working Capital $203.00M $-1.81B $662.00M $-171.00M $142.00M $-667.00M $20.00M $154.00M $220.00M $-548.00M $153.00M $-397.00M $-247.00M $-704.00M $-139.00M $-331.00M $-552.00M $463.00M $-19.00M $-86.00M
Other Non Cash Items $1.15B $7.97B $5.31B $2.67B $1.65B $1.67B $2.60B $2.34B $602.00M $1.66B $-475.00M $751.00M $819.00M $2.84B $-178.00M $5.36B $339.00M $2.15B $113.00M $538.00M
Net Cash Provided by Operating Activities $5.45B $2.27B $4.04B $4.75B $7.57B $6.32B $4.19B $7.43B $7.60B $5.00B $4.91B $5.08B $7.93B $4.89B $4.88B $4.85B $5.83B $3.09B $3.81B $3.27B
Investments in Property Plant and Equipment $-249.00M $-241.00M $-193.00M $-205.00M $-219.00M $-178.00M $-175.00M $-213.00M $-177.00M $-143.00M $-162.00M $-187.00M $-217.00M $-195.00M $-188.00M $-279.00M $-217.00M $-177.00M $-125.00M $-163.00M
Acquisitions Net $-8.29B $-843.00M $-9.20B $-553.00M $-157.00M $-160.00M $-353.00M $-300.00M $-100.00M $-209.00M $-185.00M $-1.06B $-492.00M $-147.00M $-198.00M $-400.00M $-880.00M $-38.32B $-12.00M $-659.00M
Purchases of Investments $-24.00M $-16.00M $-6.00M $-34.00M $-8.00M $-16.00M $-19.00M $-10.00M $-17.00M $-5.00M $-1.41B $-46.00M $-17.00M $-40.00M $-16.00M $-14.00M $-15.00M $-19.00M $-13.00M $-4.00M
Sales Maturities of Investments $507.00M $3.00M $6.00M $14.00M $5.00M $14.00M $22.00M $70.00M $1.41B $42.00M $8.00M $10.00M $23.00M $54.00M $11.00M $61.00M $35.00M $1.40B $26.00M $44.00M
Other Investing Activities $-196.00M $-848.00M $-196.00M $-22.00M $10.00M $-1.00M $26.00M $5.00M $170.00M $445.00M $154.00M $143.00M $88.00M $86.00M $49.00M $5.00M $-72.00M $1.46B $-5.00M $167.00M
Net Cash Used for Investing Activities $-8.26B $-1.10B $-9.59B $-800.00M $-369.00M $-341.00M $-499.00M $-448.00M $1.29B $130.00M $-1.59B $-1.15B $-615.00M $-242.00M $-342.00M $-627.00M $-1.15B $-35.65B $-129.00M $-615.00M
Debt Repayment $-403.00M $-3.35B $14.86B $-1.79B $-2.00M $-1.00B $-1.35B $-6.85B $-2.70B $-2.00M $-2.88B $-3.75B $-1.20B $-3.46B $- $-1.27B $-651.00M $- $- $28.42B
Common Stock Issued $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock Repurchased $-17.00M $-9.00M $-1.32B $-3.00M $-4.00M $-10.00M $-1.96B $-4.00M $-4.00M $-9.00M $-1.47B $-131.00M $-6.00M $-10.00M $-787.00M $-296.00M $-20.00M $-19.00M $-643.00M $-2.00M
Dividends Paid $-2.75B $-2.75B $-2.77B $-2.63B $-2.63B $-2.62B $-2.66B $-2.51B $-2.50B $-2.51B $-2.53B $-2.31B $-2.31B $-2.31B $-2.32B $-2.10B $-2.10B $-1.75B $-1.76B $-1.59B
Other Financing Activities $99.00M $10.00M $52.00M $-26.00M $-28.00M $-283.00M $-225.00M $-273.00M $-309.00M $-161.00M $-97.00M $-141.00M $-121.00M $-103.00M $-65.00M $-29.00M $-43.00M $-799.00M $-16.00M $-218.00M
Net Cash Used Provided by Financing Activities $-3.07B $-6.10B $10.82B $-4.45B $-2.66B $-3.92B $-6.19B $-9.63B $-5.52B $-2.68B $-6.97B $-6.34B $-3.64B $-5.88B $-3.17B $-3.69B $-2.81B $-2.57B $-2.42B $26.60B
Effect of Forex Changes on Cash $8.00M $-9.00M $-18.00M $23.00M $-16.00M $-10.00M $8.00M $23.00M $-59.00M $-33.00M $7.00M $-28.00M $-41.00M $27.00M $-55.00M $27.00M $6.00M $8.00M $-46.00M $14.00M
Net Change in Cash $-5.87B $-4.94B $5.25B $-473.00M $4.53B $2.05B $-2.49B $-2.63B $3.31B $2.42B $-3.65B $-2.44B $3.64B $-1.21B $1.31B $559.00M $1.87B $-35.12B $1.22B $29.28B
Cash at End of Period $7.26B $13.13B $18.07B $12.81B $13.29B $8.76B $6.71B $9.20B $11.83B $8.52B $6.10B $9.75B $12.18B $8.55B $9.76B $8.45B $7.89B $6.02B $41.14B $39.92B
Cash at Beginning of Period $13.13B $18.07B $12.81B $13.29B $8.76B $6.71B $9.20B $11.83B $8.52B $6.10B $9.75B $12.18B $8.55B $9.76B $8.45B $7.89B $6.02B $41.14B $39.92B $10.65B
Operating Cash Flow $5.45B $2.27B $4.04B $4.75B $7.57B $6.32B $4.19B $7.43B $7.60B $5.00B $4.91B $5.08B $7.93B $4.89B $4.88B $4.85B $5.83B $3.09B $3.81B $3.27B
Capital Expenditure $-249.00M $-241.00M $-193.00M $-205.00M $-219.00M $-178.00M $-175.00M $-213.00M $-177.00M $-143.00M $-162.00M $-187.00M $-217.00M $-195.00M $-188.00M $-279.00M $-217.00M $-177.00M $-125.00M $-163.00M
Free Cash Flow $5.20B $2.03B $3.85B $4.55B $7.36B $6.14B $4.02B $7.21B $7.42B $4.86B $4.75B $4.89B $7.72B $4.70B $4.69B $4.58B $5.61B $2.91B $3.69B $3.11B


AbbVie Stock Forecast

Analyst ratings, price targets, and earnings estimates for ABBV.

ABBV Analyst Ratings

Moderate Buy

Buy
22
Hold
10
Sell
0

Based on 32 analysts in the past 3 months

ABBV Stock 12 Month Forecast

$214.33

▲ (11.03% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$214.33 (11.0%)
Lowest Price Target
$ (0.0%)

Based on 3 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $60.53B
Average $59.42B
Low $58.85B
18 analysts
Net Income Estimates
High $22.51B
Average $21.86B
Low $21.21B
18 analysts
EPS Estimates
High $12.69
Average $12.27
Low $11.96
16 analysts
Revenue Estimates
High $66.60B
Average $63.95B
Low $62.75B
20 analysts
Net Income Estimates
High $26.51B
Average $24.96B
Low $23.41B
20 analysts
EPS Estimates
High $14.95
Average $13.92
Low $13.20
16 analysts
Revenue Estimates
High $68.41B
Average $68.39B
Low $68.38B
17 analysts
Net Income Estimates
High $33.02B
Average $25.95B
Low $18.87B
17 analysts
EPS Estimates
High $18.62
Average $15.50
Low $10.65
6 analysts
Revenue Estimates
High $74.66B
Average $72.40B
Low $70.40B
8 analysts
Net Income Estimates
High $31.25B
Average $30.03B
Low $28.95B
8 analysts
EPS Estimates
High $17.62
Average $16.94
Low $16.33
3 analysts
Revenue Estimates
High $78.38B
Average $76.01B
Low $73.90B
13 analysts
Net Income Estimates
High $33.74B
Average $32.42B
Low $31.26B
13 analysts
EPS Estimates
High $19.03
Average $18.29
Low $17.63
3 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Feb 03, 2025 Gary Nachman Raymond James $220.00 $190.14 15.7%
Feb 03, 2025 Evan Seigerman BMO Capital $215.00 $190.14 13.1%
Nov 12, 2024 Evan David Seigerman BMO Capital $208.00 $201.61 3.2%
Oct 31, 2024 Evan David Seigerman BMO Capital $228.00 $201.50 13.2%
Oct 31, 2024 Charlie Yang Bank of America Securities $210.00 $201.50 4.2%
Oct 31, 2024 Geoff Meacham Citigroup $226.00 $201.50 12.2%
Oct 18, 2024 Geoff Meacham Bank of America Securities $195.00 $188.57 3.4%
Oct 17, 2024 Courtney Breen Bernstein $203.00 $190.46 6.6%
Aug 23, 2024 Christopher Raymond Raymond James $209.00 $197.35 5.9%
Jul 19, 2024 Evan Seigerman BMO Capital $214.00 $172.01 24.4%

AbbVie Dividends

Explore AbbVie's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

3.85%

Dividend Payout Ratio

216.72%

Dividend Paid & Capex Coverage Ratio

2.02x



AbbVie Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$1.64 $1.64 January 15, 2025 January 15, 2025 February 14, 2025 October 30, 2024
$1.55 $1.55 October 15, 2024 October 15, 2024 November 15, 2024 September 06, 2024
$1.55 $1.55 July 15, 2024 July 15, 2024 August 15, 2024 June 20, 2024
$1.55 $1.55 April 12, 2024 April 15, 2024 May 15, 2024 February 15, 2024
$1.55 $1.55 January 12, 2024 January 16, 2024 February 15, 2024 October 27, 2023
$1.48 $1.48 October 12, 2023 October 13, 2023 November 15, 2023 September 08, 2023
$1.48 $1.48 July 13, 2023 July 14, 2023 August 15, 2023 June 22, 2023
$1.48 $1.48 April 13, 2023 April 14, 2023 May 15, 2023 February 16, 2023
$1.48 $1.48 January 12, 2023 January 13, 2023 February 15, 2023 October 28, 2022
$1.41 $1.41 October 13, 2022 October 14, 2022 November 15, 2022 September 09, 2022
$1.41 $1.41 July 14, 2022 July 15, 2022 August 15, 2022 June 23, 2022
$1.41 $1.41 April 13, 2022 April 15, 2022 May 16, 2022 February 17, 2022
$1.41 $1.41 January 13, 2022 January 14, 2022 February 15, 2022 October 29, 2021
$1.3 $1.3 October 14, 2021 October 15, 2021 November 15, 2021 September 10, 2021
$1.3 $1.3 July 14, 2021 July 15, 2021 August 16, 2021 June 17, 2021
$1.3 $1.3 April 14, 2021 April 15, 2021 May 14, 2021 February 18, 2021
$1.3 $1.3 January 14, 2021 January 15, 2021 February 16, 2021 October 30, 2020
$1.18 $1.18 October 14, 2020 October 15, 2020 November 16, 2020 September 11, 2020
$1.18 $1.18 July 14, 2020 July 15, 2020 August 14, 2020 June 17, 2020
$1.18 $1.18 April 14, 2020 April 15, 2020 May 15, 2020 February 20, 2020

Peers: Drug Manufacturers - General

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
MRK Logo
Merck & Co., Inc.
MRK
$223.05B $88.17 $0.14 $778.71 $7.56
PFE Logo
Pfizer Inc.
PFE
$146.77B $25.90 $0.38 $76.67 $1.83
LLY Logo
Eli Lilly and Company
LLY
$828.37B $872.60 $5.83 $100.04 $48.67
BMY Logo
Bristol-Myers Squibb Company
BMY
$116.72B $57.55 $3.88 $13.23 $3.61
JNJ Logo
Johnson & Johnson
JNJ
$369.43B $153.44 $13.88 $11.30 $5.77
AMGN Logo
Amgen Inc.
AMGN
$160.02B $297.70 $7.62 $34.22 $0.00
GILD Logo
Gilead Sciences, Inc.
GILD
$123.02B $98.71 $4.54 $17.85 $4.43
Current Reports (8-K)
Ownership